Valuation: Gilead Sciences, Inc.

Market Cap 161B 141B 130B 120B 227B 15,535B 231B 1,555B 610B 7,593B 606B 593B 26,172B P/E 2026 *
-46.8x
P/E 2027 * 16.5x
Enterprise Value 171B 149B 138B 127B 240B 16,446B 244B 1,646B 646B 8,038B 642B 628B 27,705B EV / Sales 2026 *
5.61x
EV / Sales 2027 * 4.98x
Free-Float
99.88%
Yield 2026 *
2.5%
Yield 2027 * 2.59%
1 day+2.00%
1 week-2.13%
Current month+5.22%
1 month+6.94%
3 months-4.89%
6 months+9.62%
Current year+8.30%
1 week 127.94
Extreme 127.935
136.06
1 month 122.43
Extreme 122.43
137.7
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
Jun. 30Sell

Chief Executive Officer

-15,000 0.0012%
Jun. 14Sell

Executive/Senior Manager

-3,000 0.0002%
Jun. 14Sell

Chief Financial Officer

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+2.05%-2.13%+21.89%+71.57% 161B
-0.83%-6.13%+47.88%+155.24% 1,028B
-0.93%-4.77%+61.65%+57.69% 611B
+1.68%-2.14%+32.69%+83.44% 432B
+0.98%-1.40%+29.49%+23.12% 323B
-0.34%-3.10%+27.00%+43.66% 277B
+1.63%-11.76%+19.72%+23.20% 257B
+3.39%+2.29%-23.68%-38.33% 217B
+1.11%-2.30%+22.91%+57.79% 192B
+2.04%+2.99%+0.65%-30.93% 138B
Average +1.09%-4.64%+24.02%+44.64% 363.65B
Weighted average by Cap. +0.43%-5.28%+34.65%+73.28%

Financials

2026 *2027 *
Net sales 30.47B 26.64B 24.57B 22.59B 42.8B 2,932B 43.53B 293B 115B 1,433B 114B 112B 4,939B 32.39B 28.32B 26.13B 24.02B 45.51B 3,117B 46.28B 312B 122B 1,524B 122B 119B 5,251B
Net income -3.39B -2.96B -2.73B -2.51B -4.76B -326B -4.85B -32.65B -12.81B -159B -12.73B -12.46B -550B 9.76B 8.53B 7.87B 7.24B 13.71B 939B 13.95B 93.99B 36.88B 459B 36.66B 35.86B 1,582B
Net Debt 9.46B 8.27B 7.63B 7.01B 13.29B 910B 13.52B 91.09B 35.74B 445B 35.53B 34.75B 1,534B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-15 $132.10 +1.58% 2,270,177
26-07-14 $130.04 -1.04% 5,255,960
26-07-13 $131.40 +1.21% 5,131,594
26-07-10 $129.83 -3.72% 5,935,997
26-07-09 $134.84 -0.72% 5,839,339
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
130.04USD
Average target price
158.30USD
Spread / Average Target
+21.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock